The microarray analysis market was around $3,847 million in the year 2021, and will reach over $9,011 million in the future. The main factors responsible for the growing use of this procedure comprise the increasing occurrence of cancer, initiatives by the government for genomic research, and the increasing purposes of microarrays. This kind of analysis is mostly used in biomarker identification, pharmaceutical screening, and toxicology screening, to recognize the alteration in the DNA. Furthermore, microarray analysis is used for screening numerous genes at once.
DNA microarrays had the most demand. This is because DNA microarrays are employed in clinical diagnostic tests for numerous diseases. They are used to find out which medicine is best for a specific patient because genes govern how the body handles medicine. These are also used for identifying the mutation in the gene structure.
Approximately 2 million new cases of cancer are diagnosed and nearly 609,000 deaths are likely from cancer in the U.S. in 2022. As per the estimates of the American Cancer Society, about 1,918,030 Americans will be identified with cancer, and nearly 5,250 new cases detected every day. This is more than about 1.8 million new cases that happened in 2021.
Microarray examination has come in handy in antibiotic therapy since bacterial genomic DNA mostly lives longer than the bacteria in such conditions, DNA microarrays are generally used, since an analysis may be done with a small amount of DNA, rather than the larger count of bacteria needed for culture. Recently, DNA-based microarrays are the first choice for the measurement of gene expression. This is generally because of the lower intricacy and usage cost, allowing this technology to be developed into one, which is more accessible and standardized.
With the increasing incidences of cancer, the demand for the procedure of microarray analysis is on the rise.
Browse detailed report on Microarray Analysis Market Size, and Regional Outlook
